Patients who received the treatment had less severe brain symptoms and better daily functioning 90 days after the stroke, as compared with those who received clot treatment and a placebo medication.
Butylphthalide is approved and available for use in China, where the study was done. But the medication hasn’t been approved for use by the FDA.
“This is the first trial to show the benefit of using a medication that protects the brain from damage caused by a lack of oxygen to brain tissue. The medication was given to patients with acute ischemic stroke who were also receiving treatment to restore blood flow to the brain,” says co-author Baixue Jia, MD, a doctor of interventional neuroradiology at the Beijing Tiantan Hospital and the China National Clinical Research Center for Neurological Diseases in Beijing.
Comments are closed.